Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBIT (2016 - 2025)

Enanta Pharmaceuticals' EBIT history spans 14 years, with the latest figure at -$11.3 million for Q4 2025.

  • For Q4 2025, EBIT rose 52.2% year-over-year to -$11.3 million; the TTM value through Dec 2025 reached -$73.1 million, up 33.79%, while the annual FY2025 figure was -$85.3 million, 29.86% up from the prior year.
  • EBIT reached -$11.3 million in Q4 2025 per ENTA's latest filing, up from -$18.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$11.3 million in Q4 2025 to a low of -$39.5 million in Q1 2023.
  • Average EBIT over 5 years is -$28.8 million, with a median of -$30.2 million recorded in 2021.
  • Peak YoY movement for EBIT: tumbled 150.11% in 2021, then soared 52.2% in 2025.
  • A 5-year view of EBIT shows it stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then fell by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then skyrocketed by 52.2% to -$11.3 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's EBIT are -$11.3 million (Q4 2025), -$18.4 million (Q3 2025), and -$18.9 million (Q2 2025).